----

----

| Colorado                                                       |   | 84-1307164                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |

|   | Large accelerated filer | o | Accelerated filer         | o                         |
|--------|-------------------------|---|---------------------------|---------------------------|
|   | Non-accelerated filer   | o | Smaller reporting company | x     |

----

Table of Contents

----

Table of Contents

ON

|                 | Page                                       |
|----------------------|--------------------------------------------|
| FINANCIAL STATEMENTS |                                       |
|                 | Balance sheets                             | 4 |
|                 | Statements of operation                    | 5 |
|                 | Statements of cash flows                   | 6 |
|                 | Notes to consolidated financial statements | 8 |

----

Table of Contents

| NANO LABS CORP.                            |   |
|--------------------------------------------|--------|
| BALANCE SHEETS                             |   |
|                                       |   |   |   |   |   |   |
|                                       |   |   |   |   | Mar. 31, 2013 |   |
|                                       |   | June 30, 2012 |   |   | (Unaudited) |   |
|                                       |   |   |   |   |   |   |
| ASSETS                                     |   |   |   |   |   |   |
|                                       |   |   |   |   |   |   |
| Current assets                             |   |   |   |   |   |   |
| Cash                                       |   | $ | - |   |   | $ | 166,110 |   |
| Total current assets                       |   |   | - |   |   |   | 166,110 |   |
|                                       |   |   |   |   |   |   |   |   |
| Intellectual property                      |   |   | - |   |   |   | 18,000 |   |
|                                       |   |   | - |   |   |   | 18,000 |   |
|                                       |   |   |   |   |   |   |   |   |
| Total Assets                               |   | $ | - |   |   | $ | 184,110 |   |
|                                       |   |   |   |   |   |   |   |   |
| LIABILITIES & STOCKHOLDERS' EQUITY     |   |   |   |   |   |   |   |   |
|                                       |   |   |   |   |   |   |   |   |
| Current liabilities                        |   |   |   |   |   |   |   |   |
| Accounts payable                           |   | $ | 161,566 |   |   | $ | 98,008 |   |
| Related party payables                     |   |   | 200 |   |   |   | 201,421 |   |
| Notes payable - current - rel. party       |   |   | - |   |   |   | 350,000 |   |
| Notes payable - current                    |   |   | 47,023 |   |   |   | - |   |
| Accrued interest payable                   |   |   | 226 |   |   |   | - |   |
| Total current liabilities                  |   |   | 209,015 |   |   |   | 649,429 |   |
|                                       |   |   |   |   |   |   |   |   |
| Total Liabilities                          |   |   | 209,015 |   |   |   | 649,429 |   |
|                                       |   |   |   |   |   |   |   |   |
| Stockholders' Equity                       |   |   |   |   |   |   |   |   |
| Preferred stock, $.001 par value;          |   |   |   |   |   |   |   |   |
| 10,000,000 shares authorized;              |   |   |   |   |   |   |   |   |
| No shares issued & outstanding         |   |   | - |   |   |   | - |   |
| Common stock, $.001 par value;             |   |   |   |   |   |   |   |   |
| 500,000,000 shares authorized;             |   |   |   |   |   |   |   |   |
| 179,125,000 shares                         |   |   |   |   |   |   |   |   |
| issued and outstanding                     |   |   | 179,125 |   |   |   | 179,125 |   |
| Additional paid in capital                 |   |   | 197,341 |   |   |   | 315,069 |   |
| Accumulated deficit                        |   |   | (585,481 | ) |   |   | (959,513 | ) |
| Total Stockholders' Equity                 |   |   | (209,015 | ) |   |   | (465,319 | ) |
|                                       |   |   |   |   |   |   |   |   |
| Total Liabilities and Stockholders' Equity |   | $ | - |   |   | $ | 184,110 |   |

----

Table of Contents

| NANO LABS CORP.                            |   |
|--------------------------------------------|--------|
| STATEMENTS OF OPERATIONS                   |   |
| (Unaudited)                                |   |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |
|                                       |   | Three Months |   |   | Three Months |   |   | Nine Months |   |   | Nine Months |   |
|                                       |   | Ended |   |   | Ended |   |   | Ended |   |   | Ended |   |
|                                       |   | Mar. 31, 2012 |   |   | Mar. 31, 2013 |   |   | Mar. 31, 2012 |   |   | Mar. 31, 2013 |   |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |
| Revenues                                   |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |
| Operating expenses:                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| General and administrative                 |   |   | - |   |   |   | 251,270 |   |   |   |   |   |   |   | 374,032 |   |
|                                       |   |   | - |   |   |   | 251,270 |   |   |   | - |   |   |   | 374,032 |   |
| Gain (loss) from operations                |   |   | - |   |   |   | (251,270 | ) |   |   | - |   |   |   | (374,032 | ) |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other income (expense):                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                       |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Income (loss) from continuing operations   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| before provision for income taxes          |   |   | - |   |   |   | (251,270 | ) |   |   | - |   |   |   | (374,032 | ) |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Provision for income tax                   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) from continuing operations   |   | $ | - |   |   | $ | (251,270 | ) |   | $ | - |   |   | $ | (374,032 | ) |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Discontinued operations:                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) from discontinued operations |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (including loss on disposal of $0) -       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| net of tax                                 |   |   | (33,395 | ) |   |   | - |   |   |   | (24,978 | ) |   |   | - |   |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income (loss)                          |   | $ | (33,395 | ) |   | $ | (251,270 | ) |   | $ | (24,978 | ) |   | $ | (374,032 | ) |
| Net income (loss) per share                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (Basic and fully diluted):                 |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Continuing operations                      |   |   | - |   |   |   | (0.00 | ) |   |   | (0.00 | ) |   |   | (0.00 | ) |
| Discontinued operations                    |   |   | (0.00 | ) |   |   | - |   |   |   | - |   |   |   | - |   |
| Total operations                           |   | $ | (0.00 | ) |   | $ | (0.00 | ) |   | $ | (0.00 | ) |   | $ | (0.00 | ) |
|                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average number of                 |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| common shares outstanding                  |   |   | 203,125,000 |   |   |   | 179,125,000 |   |   |   | 203,125,000 |   |   |   | 179,125,000 |   |

----

Table of Contents

| NANO LABS CORP.                                      |   |
|------------------------------------------------------|--------|
| STATEMENTS OF CASH FLOWS                             |   |
| (Unaudited)                                          |   |
|                                                 |   |   |   |   |   |   |
|                                                 |   |   |   |   |   |   |
|                                                 |   | Nine Months |   |   | Nine Months |   |
|                                                 |   | Ended |   |   | Ended |   |
|                                                 |   | Mar. 31, 2012 |   |   | Mar. 31, 2013 |   |
|                                                 |   |   |   |   |   |   |
| Cash Flows From Operating Activities:                |   |   |   |   |   |   |
| Net income (loss)                                    |   | $ | (24,978 | ) |   | $ | (374,032 | ) |
|                                                 |   |   |   |   |   |   |   |   |
| Adjustments to reconcile net loss to                 |   |   |   |   |   |   |   |   |
| net cash provided by (used for)                      |   |   |   |   |   |   |   |   |
| operating activities:                                |   |   |   |   |   |   |   |   |
| Accrued payables                                     |   |   | - |   |   |   | 208,142 |   |
| Discontinued operations                              |   |   | 24,978 |   |   |   | - |   |
| Net cash provided by (used for) operating activities |   |   | - |   |   |   | (165,890 | ) |
|                                                 |   |   |   |   |   |   |   |   |
| Cash Flows From Investing Activities:                |   |   |   |   |   |   |   |   |
| Intellectual property                                |   |   | - |   |   |   | (18,000 | ) |
| Net cash provided by (used for)investing activities  |   |   | - |   |   |   | (18,000 | ) |
|                                                 |   |   |   |   |   |   |   |   |
|                                                 |   |   |   |   |   |   |   |   |
|                                                 |   |   |   |   |   |   |   |   |
|                                                 |   |   |   |   |   |   |   |   |
| (Continued On Following Page)                        |   |

----

Table of Contents

| NANO LABS CORP.                                                                                                  |   |
|------------------------------------------------------------------------------------------------------------------|--------|
| STATEMENTS OF CASH FLOWS                                                                                         |   |
| (Unaudited)                                                                                                      |   |
|                                                                                                             |   |   |   |   |   |   |
|                                                                                                             |   |   |   |   |   |   |
| (Continued From Previous Page)                                                                                   |   |
|                                                                                                             |   |   |   |   |   |   |
|                                                                                                             |   |   |   |   |   |   |
|                                                                                                             |   |   |   |   |   |   |
|                                                                                                             |   | Nine Months |   |   | Nine Months |   |
|                                                                                                             |   | Ended |   |   | Ended |   |
|                                                                                                             |   | Mar. 31, 2012 |   |   | Mar. 31, 2013 |   |
|                                                                                                             |   |   |   |   |   |   |
| Cash Flows From Financing Activities:                                                                            |   |   |   |   |   |   |
| Notes payable - borrowings                                                                                       |   |   | - |   |   |   | 350,000 |   |
| Net cash provided by (used for)  financing activities                                                  |   |   | - |   |   |   | 350,000 |   |
|                                                                                                             |   |   |   |   |   |   |   |   |
| Net Increase (Decrease) In Cash                                                                                  |   |   | - |   |   |   | 166,110 |   |
|                                                                                                             |   |   |   |   |   |   |   |   |
| Cash At The Beginning Of The Period                                                                              |   |   | - |   |   |   | - |   |
|                                                                                                             |   |   |   |   |   |   |   |   |
| Cash At The End Of The Period                                                                                    |   | $ | - |   |   | $ | 166,110 |   |
|                                                                                                             |   |   |   |   |   |   |   |   |
|                                                                                                             |   |   |   |   |   |   |   |   |
| In fiscal year ended June 2012, the Company recorded $117,728 in paid in capital from related party debt relief. |   |
|                                                                                                             |   |   |   |   |   |   |   |   |
|                                                                                                             |   |   |   |   |   |   |   |   |
| Supplemental Disclosure:                                                                                         |   |   |   |   |   |   |   |   |
| Cash paid for interest                                                                                           |   | $ | - |   |   | $ | - |   |
| Cash paid for income taxes                                                                                       |   | $ | - |   |   | $ | - |   |

----

Table of Contents

AB

----

Table of Contents

----

Table of Contents

|   | 1) | transferring all of its assets to CCT, Inc., a wholly-owned subsidiary of the Company;                                              |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------|
|   | 2) | selling CCT, Inc. to Sandie Venezia, a former officer and director of the Company, for $500;                                        |
|   | 3) | changing the name of the Company to Nano Labs Corp.;                                                                                |
|   | 4) | changing the authorized capital of the Company to 500,0000,000 shares of common stock and 10,000,000 shares of preferred stock; and |
|   | 5) | forward splitting the Company’s common stock on a 25 for 1 basis.                                                             |

|   | ● | the Company acquired new nanotechnology from Dr. Victor Castano in exchange for 101,000,000 shares of the Company’s common stock. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------|
|   |    |                                                                                                                                    |
|   | ● | the Company appointed Dr. Castano as a Director and as its Chief Technological and Scientific Officer.                                  |
|   |    |                                                                                                                                    |
|   | ● | Jose Manual Flores Hernandez resigned as an Officer and Director.                                                                       |

----

Table of Contents

|                                               |   | Projected       |
|----------------------------------------------------|--------|-----------------|
| Activity                                           |   | Completion Date |
|                                               |   |            |
| Nano Coating                                       |   |            |
| Manufacture coatings using third party contractors |   | June 1, 2013    |
| Marketing of new Nano Coating                      |   | June 15, 2013   |

| Nano Laquer                           |   |              |
|---------------------------------------|--------|-------------------|
| Manufacture Nano Lacquer Nail Polish  |   | August 1, 2013    |
| Marketing of Nano Lacquer Nail Polish |   | September 1, 2013 |

----

Table of Contents

----

Table of Contents

| Exhibits |                                                                     |
|----------|--------------------------------------------------------------------------|
|     |                                                                     |
| 31.1     | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2     | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32       | Certification pursuant to Section 906 of the Sarbanes-Oxley Act.         |

----

Table of Contents

|                     | NANO LABS CORP.      |                                                      |
|--------------------------|-----------------------------------------------|-----------------------------------------------------------|
|                     |                                          |                                                      |
|                     |                                          |                                                      |   |
| May 14, 2013   | By:                                           | /s/ Bernardo Camacho Chavarria                       |   |
|                     |                                          | Bernardo Camacho Chavarria,      |   |
|                     |                                          | Principal Executive, Financial and                        |   |
|                     |                                          | Accounting Officer                                        |   |

----